Budd‑Chiari syndrome – hematologists’ part in the multidisciplinary approach

Czech version

Authors: P. Ďulíček; J. Malý
Authors‘ workplace: Oddělení klinické hematologie II. interní kliniky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.
Published in: Vnitř Lék 2008; 54(9): 842-845
Category: Reviews

Overview

Budd‑Chiari syndrome presents a serious disease with a complex etiology and clinical manifestations, which is associated with high morbidity and mortality. An early diagnosis and therapy is mandatory due to the severity of disease and therapy contains the treatment of underlying disorder, anticoagulation therapy and therapy of liver impairment. We discuss hematologists’ contribution to the diagnostic approach and therapy of this syndrome.

Key words:
Budd‑Chiari syndrome – hematological disorders – therapy

Sources

1. Aydinli M, Bayraktar Y. Budd‑Chiari syndrome: etiology, pathogenesis and diagnosis. World J Gastroenterol 2007; 13: 2693–2696.

2. Briére JB. Budd‑Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: Diagnosis and management. Semin Tromb Hemost 2006; 32: 208–218.

3. Condat B, Pessione F, Hillaire S et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120: 490–497.

4. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275–290.

5. Horton JD, San Miquel FL, Ortiz JA. Budd‑Chiari syndrome: illustrated review of current management. Liver Int 2008; 1478: 455–466.

6. Chung RT, Iafrate AJ, Amrein PC et al. Case records of the Massachusetts ge-ne--ral hospital. Case 15–2006. A 46-year- -old-woman with sudden onset of abdominal distention. N Engl J Med 2006; 354: 2166–2175.

7. Kage M, Arakawa M, Kojiro M et al. Histopathology of membranous obstruction of the inferior vena cava in the Budd‑Chiari syndrome. Gastroenterology 1992; 102: 2081–2090.

8. Kew MC, Hodkinson HJ. Membraneous obstruction of the inferior vena cava and its causal relation to hepatocellular carcinoma. Liver Int 2006; 26: 1–7.

9. Janssen HL, Garcia-Pagan JC, Elias E et al. Budd‑Chiari syndrome: a review by an expert panel. J Hepatol 2003; 38: 364–371.

10. Langlet P, Valla D. Is surgical portosystemic shunt the treatment of choice in Budd‑Chiari syndrome? Acta Gastroenterol Belg 2002; 65: 155–160.

11. Melear JM, Goldstein RM, Levy MF et al. Hematologic aspects of liver transplantation for Budd‑Chiari syndrome with special reference to myeloproliferative disorders. Transplantation 2002; 74: 1090–1095.

12. Menon KV, Shah V, Kamath PS. The Budd‑Chiari syndrome. N Engl J Med 2004: 350: 578–585.

13. Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepa-tocavopathy). Semin Liver Dis 2002; 22: 15–26.

14. Penka M, Schwarz J, Pytlík R et al. Doporučený postup diagnostiky a terapie esenciální trombocytemie a trombocytemie provázející jiné myeloproliferativní choroby. Vnitř Lék 2005; 51: 741–751.

15. Penka M, Doubek M, Schwarz J et al. Anagrelid v léčbě esenciální trombocytemie a dalších myeloproliferací s trombocytemií sledovaných v registru pacientů ČR. Vnitř Lék 2006; 52: 498–503.

16. Robertson B, Urquhart C, Ford I et al. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V617 F status, clonality, and antiphospholipid antibodies. J Tromb Haemost 2007; 5: 1679–1685.

17. Sharma S, Texeira A, Texeira P et al. Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol 2004; 40: 172–180.

18. Schwarz J, Pytlík R, Doubek M et al. Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia. Semin Thromb Hemost 2006; 32: 231–245.

19. Terabayashi H, Okuda K, Nomura F et al. Transformation of inferior vena caval thrombosis to membraneous ob-struction in a patient with the lupus anticoagulant. Gastroenterology 1986; 91: 219–224.

20. Valla DC. Hepatic vein thrombosis (Budd‑Chiari syndrome). Semin Liver Dis 2002; 22: 14.

21. Wang ZG, Zhang FJ, Yi MQ et al. Evolution of management for Budd‑Chiari syndrome: a team’s view from 2565 patients. ANZ J Surg 2005; 75: 55–63.

22. Zimmerman MA, Cameron AM, Ghobrial RM et al. Budd‑Chiari syndrome. Clin Liver Dis 2006; 10: 259–273.